1L
ABBV icon

10Elms LLP’s AbbVie ABBV Stock Holding History

10Elms LLP’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.2K Sell
47
-47
-50% -$10.4K 0.01% 402
2025
Q4 		$21.5K Hold
94
– – 0.02% 320
2025
Q3 		$21.8K Hold
94
– – 0.02% 336
2025
Q2 		$17.4K Hold
94
– – 0.02% 358
2025
Q1 		$19.7K Hold
94
– – 0.02% 354
2024
Q4 		$16.7K Buy
+94
New +$17.3K 0.02% 365

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

10Elms LLP's ABBV Position: Q1 2026 in Review

10Elms LLP reduced its AbbVie (ABBV) stake by 50% in Q1 2026, selling an estimated $10.4K and leaving 47 shares worth $10.2K. The position accounts for 0.01% of the portfolio, ranked #402.

10Elms LLP first reported a position in ABBV in Q4 2024 and has held it in 6 quarters since. The position peaked at $21.8K in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • 10Elms LLP held 47 shares of AbbVie worth $10.2K as of Q1 2026.
  • 10Elms LLP sold 47 AbbVie shares in Q1 2026, an estimated $10.4K.
  • AbbVie made up 0.01% of 10Elms LLP's portfolio in Q1 2026, its #402 holding.
  • 10Elms LLP first reported a position in AbbVie in Q4 2024 and has held it in 6 quarters since.
  • 10Elms LLP's AbbVie position peaked at $21.8K in Q3 2025.
  • 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on 10Elms LLP's 13F filing for Q1 2026, filed 15 May 2026.